Article Text
Statistics from Altmetric.com
OpenUrlCrossRefPubMedWeb of Science
Q In patients with asthma, is budesonide (BUD) plus formoterol (FORM) (BUDFORM) for both maintenance and symptom relief more effective than fixed dosing using BUDFORM or a 4 fold higher dose of BUD, both with a short acting β2 agonist (SABA), for reducing the rate of severe asthma exacerbations?
METHODS
Design:
randomised controlled trial.
Allocation:
concealed.
Blinding:
blinded (patients and healthcare providers).
Follow up period:
1 year
Setting:
246 centres in 22 countries.
Patients:
2760 outpatients (mean age 36 y, 55% women/girls; 12% children 4–11 y) with asthma who were using inhaled corticosteroids (ICSs).
Intervention:
BUDFORM (BUD, 80 μg plus FORM, 4.5 μg) both for …
Footnotes
For correspondence: Dr P M O’Byrne, St Joseph’s Hospital, Hamilton, Ontario, Canada. obyrnepmcmaster.ca
Source of funding: AstraZeneca R&D, Lund, Sweden.